IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022
IsoPlexis Corporation (NASDAQ: ISO) will release its Q2 2022 financial results on August 10, 2022, before the market opens.
Rhea-AI Summary
IsoPlexis Corporation (NASDAQ: ISO) will release its Q2 2022 financial results on August 10, 2022, before the market opens. A conference call is scheduled for 5:30 a.m. PT / 8:30 a.m. ET. The event will be available for live streaming on the company's website and archived for later replay.
As a leader in immune cell research, IsoPlexis aids researchers in understanding disease dynamics and therapeutic efficacy, gaining recognition from notable publications and being utilized by major pharmaceutical companies.
Positive
- IsoPlexis is a recognized leader in immune cell research, utilized by top pharmaceutical companies.
- Company has received accolades from The Scientist Magazine and other prestigious platforms for innovation.
Negative
- None.
Details
News Market Reaction – ISO
In the trading session that priced this news, ISO gained 8.12%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.
About IsoPlexis
IsoPlexis is the Superhuman Cell company.
By leading the discovery and identification of how multi-functional immune— Superhuman— cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.
IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and at over
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.